Virtual Discussions with Genuine Experts
COVID-19 RESEARCH WEBINAR SERIES
September 22, 2020
RACING TO BEAT COVID-19: THE OXFORD VACCINE AND OTHER TALES FROM THE UK
Sir John Bell, Regius Professor of Medicine, University of Oxford
Renowned biomedical scientist Sir John Bell is the leader of a rapidly advancing effort to deliver a vaccine that will confer immunity against SARS-CoV-2. President Rick Lifton and Professor Bell will discuss the extraordinary challenges involved in the development and international testing of a new vaccine, as well as other medical measures needed to bring COVID-19 under control.
July 9, 2020
COVID-19: WHERE ARE WE NOW AND WHERE ARE WE HEADED?
Paula Zahn and Richard P. Lifton, M.D., Ph.D.
Nine-time Emmy award-winning journalist Paula Zahn will interview President Rick Lifton in a wide-ranging conversation about COVID-19 and research at Rockefeller University.
Paula Zahn is the executive producer and host of Investigation Discovery’s On the Case with Paula Zahn, and host of WNET’s weekly arts and culture multi-platform showcase, NYC-ARTS.
Rick Lifton is president of Rockefeller University and a pioneer in the use of genetics and genomics to understand the mechanisms underlying hypertension, cardiovascular disease, osteoporosis, kidney disease, and cancer.
June 18, 2020
FIGHTING COVID-19 WITH CONVALESCENT PLASMA, POTENT ANTIBODIES, AND AN UNDERSTANDING OF IMMUNITY TO SARS-COV-2
Paul Bieniasz, Ph.D.
Virologist Paul Bieniasz and his partner, Theodora Hatziioannou, have developed techniques to measure the levels and potencies of antibodies that neutralize SARS-CoV-2. Using these approaches, their group has collaborated with investigators at Rockefeller, the New York Blood Center, and other institutions to help develop effective convalescent plasma and monoclonal antibody therapy for COVID-19 patients.
May 21, 2020
THE RACE TO CONTROL COVID-19: INNOVATIVE STRATEGIES TO DEVELOP NEW DRUGS
Charles M. Rice, Ph.D.
Virologist Charles Rice and his colleagues have identified a human cellular gene that blocks entry into cells by many types of coronaviruses, including the virus that causes COVID-19. The goal of this research is to discover drugs that will help patients during the present pandemic while developing broad-spectrum therapeutics that will also prepare us for future coronavirus outbreaks.
May 14, 2020
ANTIBODY THERAPEUTICS AND PATHWAYS TO PREVENTION
Marina Caskey, M.D.
Drawing on her studies of HIV and other infectious diseases, physician-scientist Marina Caskey is leading clinical efforts to identify and evaluate exceptionally potent antibodies derived from patients who have recovered from COVID-19. This work, in collaboration with lab head Michel Nussenzweig, M.D., Ph.D., is essential to the development of immunotherapeutic strategies for the prevention and treatment of coronavirus infection.
May 7, 2020
WHY ARE SOME YOUNG AND PREVIOUSLY HEALTHY PEOPLE VERY SICK? THE ROLE OF HUMAN GENES IN COVID-19
Jean-Laurent Casanova, M.D., Ph.D.
COVID-19 has a perplexing range of outcomes, from silent infection to mild illness to fatal respiratory disease. Age and pre-existing health conditions are not the sole risk factors, as severe disease can also strike previously healthy people under the age of 50. Jean-Laurent Casanova is searching for inborn errors of immunity—human gene variants that disrupt immune responses to this particular virus and may underlie these very severe yet unexplained cases.
April 21, 2020
ANTIBODIES AGAINST COVID-19: THE PATH TO EFFECTIVE TREATMENTS AND A VACCINE
Michel C. Nussenzweig, M.D., Ph.D.
In the first webinar of the series, President Richard P. Lifton provides an overview of Rockefeller’s COVID-19 research and immunologist Michel Nussenzweig reports on his efforts to develop an antibody-based treatment for the prevention and control of COVID-19.